These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20067754)

  • 21. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
    Wang J; Zhang W; He A; Zhao W; Cao X
    Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
    Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
    Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo.
    Linghua Z; Xingshan T; Fengzhen Z
    Int Immunopharmacol; 2006 Aug; 6(8):1267-76. PubMed ID: 16782539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by a goose parvovirus vaccine in ducks.
    Lee JW; Lin YM; Yen TY; Yang WJ; Chu CY
    Vaccine; 2010 Nov; 28(50):7956-62. PubMed ID: 20933041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2.
    Patial S; Chaturvedi VK; Rai A; Saini M; Chandra R; Saini Y; Gupta PK
    Vaccine; 2007 May; 25(20):4020-8. PubMed ID: 17391817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No adverse effects of simultaneous vaccination with the immunocontraceptive GonaCon and a commercial rabies vaccine on rabies virus neutralizing antibody production in dogs.
    Bender SC; Bergman DL; Wenning KM; Miller LA; Slate D; Jackson FR; Rupprecht CE
    Vaccine; 2009 Nov; 27(51):7210-3. PubMed ID: 19925955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus.
    Lakshmanan N; Gore TC; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2006; 7(3):223-31. PubMed ID: 17039445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of a square presentation of V-RG vaccine baits in red fox, domestic dog and raccoon dog.
    Cliquet F; Guiot AL; Schumacher C; Maki J; Cael N; Barrat J
    Dev Biol (Basel); 2008; 131():257-64. PubMed ID: 18634487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine.
    Kallel H; Diouani MF; Loukil H; Trabelsi K; Snoussi MA; Majoul S; Rourou S; Dellagi K
    Vaccine; 2006 May; 24(22):4856-62. PubMed ID: 16600442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serological response of the dog after primary antirabies vaccination using adjuvant or non-adjuvant vaccines].
    Koutchoukali MA; Blancou J; Chappuis G; Tixier G; Eloit M; Ganiere JP; Chantal J; Simon S; Berthier A; Toma B
    Ann Rech Vet; 1985; 16(4):345-9. PubMed ID: 4091488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide.
    Mahmood MS; Siddique M; Hussain I; Khan A; Mansoor MK
    Vaccine; 2006 May; 24(22):4838-46. PubMed ID: 16600440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rabies vaccinations.
    Parry J
    Vet Rec; 2000 May; 146(20):591. PubMed ID: 10839239
    [No Abstract]   [Full Text] [Related]  

  • 35. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and bait acceptance of vaccinia vectored rabies glycoprotein vaccine in captive foxes (Vulpes vulpes), raccoon dogs (Nyctereutes procyonoides) and dogs (Canis familiaris).
    Cliquet F; Barrat J; Guiot AL; Caël N; Boutrand S; Maki J; Schumacher CL
    Vaccine; 2008 Aug; 26(36):4627-38. PubMed ID: 18620017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
    Abe N; Kodama S; Hirano T; Eto M; Suzuki M
    Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant activity of PCP-II, a polysaccharide from Poria cocos, on a whole killed rabies vaccine.
    Zhang W; Cheng N; Wang Y; Zheng X; Zhao Y; Wang H; Wang C; Han Q; Gao Y; Shan J; Yang S; Xia X
    Virus Res; 2019 Sep; 270():197638. PubMed ID: 31173772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of canine oral rabies vaccination in Sri Lanka--a preliminary report.
    Perera MA; Harischandra PA; Wimalaratne O; Damboragama SN
    Ceylon Med J; 2000 Jun; 45(2):61-4. PubMed ID: 11051702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
    Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
    Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.